| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nemolizumab | CD-14152; CIM-331 | Approved | Chugai Pharmaceutical Co Ltd | Mitchga, Nemluvio | Japan | Pruritus; Dermatitis, Atopic | Maruho Co Ltd | 2022-03-28 | Pruritus; Scleroderma, Systemic; Prurigo; Renal Insufficiency, Chronic; Dermatitis, Atopic | Details |